Introduction
Following our initial exploratory study, this second MOST study focused on assessing the safety and stability of supplementing with all three macular carotenoids: lutein, zeaxanthin, and meso-zeaxanthin. This research was critical to ensure that our supplement met the highest standards before advancing to larger clinical trials.
Why was the research undertaken?
Before scaling up our clinical research, it was essential to demonstrate that the triple-carotenoid supplement was safe for human use and remained stable over time. We needed to rule out any adverse effects by conducting thorough clinical pathology testing and to confirm the supplement’s continued efficacy.
How was the study conducted?
Working closely with a clinical pathology laboratory, we monitored key blood markers and safety parameters in participants who took the carotenoid supplement. Alongside safety testing, we assessed the stability of the supplement formulation and measured participants’ blood carotenoid levels as well as macular pigment changes.
What were the results?
Our findings showed that the supplement was completely safe, with no negative effects detected in the detailed clinical pathology analyses. Participants demonstrated a strong positive blood response to supplementation, consistent with our initial trial results, and we observed an increase in macular pigment. Stability testing confirmed that the supplement maintained its quality throughout the study period.
What is the societal benefit?
By confirming the safety and stability of this new triple-carotenoid formulation, this study laid the foundation for larger, more ambitious trials focused on visual performance and eye health benefits. It supports the development of a scientifically validated, well-tolerated nutritional intervention designed to protect and enhance eye function, especially for those at risk of visual decline.
